hypertension with asyptomatic hyperuricemia
Conditions
Interventions
invention group:anti-hypertension, life style invention and Benzbronmarone
Sponsors
China-Japan friendship hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. participants with age between eighteen to sixty years old, male or female; 2. body mass index 420 umol/L (7 mg/dL); 5. participants must sign informed consent; 6. type of uric acid discharge poor: uric acid drainage less than 0.48 mg/kg/h, uric acid clearance (Cua, urinary uric acid * every minute urine volume/serum uric acid) < 6.2 ml/min. the Cua/Ccr ratio < 5%.
Exclusion criteria
Exclusion criteria: 1. SBP >180 MMHG; 2. DBP >110 MMHG; 3. gout; 4. uric acid type(generate too much): uric acid discharge more than 0.51 mg/kg/h, uric acid clearance rate was 6.2 ml/min.; 5. secondary hypertension; 6. a history of heart cerebrovascular disease (such as coronary heart disease, myocardial infarction, heart failure, stroke, transient ischemic attack (TIA); 7. always used diuretics and beta-blocker; 8. used promoting blood uric acid agents ago; 9. heparin (including low molecular heparin) treatment; 10. need to use anti-arrhythmia drug; 11. use drugs including diuretics and other influence uric acid; 12. use systemic corticosteroids drugs and non-steroidal anti-inflammatory drugs (NSAIDs); 13. drug abuser or drunkard; 14. pregnancy and lactation; 15. clinical trial enrolling in the past 30 days; 16. participants with some diseases are not suitable to enrolling the trial according to the researchers' judgment; 17. allergy to benzbromarone; 18. patients must use beta blockers (including ophthalmic), diureticsin after entering this test period (2 weeks follow-up); 19. with a personal or family history of psoriasis; 20. serum creatinine values was below 1.5 mg/dL, and Ccr 3 * ULN, total bilirubin > 2 * ULN).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the flow mediated dilation, FMD;Pulse wave velocity, PWV;endothelial Microparticles EM; | — |
Secondary
| Measure | Time frame |
|---|---|
| hyper- sensitivity C -reactive protein hs-CRP;urinary microalbuminuria, UMA;atherogenic index of plasma, AI; | — |
Countries
China
Contacts
Public ContactJiao Yuan
China-Japan friendship Hospital
Outcome results
None listed